WASHINGTON (August 28, 2026) — The Association for Accessible Medicines today commented on the announcement by Somerset Pharma, LLC, a member of AAM, on the
Adds Chicago research and development facility, New Jersey manufacturing site WASHINGTON (August 21, 2026) — The Association for Accessible Medicines today commented on the announcement
By John Murphy, President and CEO, Association for Accessible Medicines There is a temptation, when looking at new data on drug shortages, to focus on
Legislation codifies FDA’s science-based approach to biosimilar review by limiting comparative efficacy studies; Introduced and Passed House Committee This Week WASHINGTON (July 23, 2026) —
Legislative progress codifies FDA’s science-based approach to biosimilar review by limiting comparative efficacy studies; Eliminates arbitrary distinction between interchangeable biologics and biosimilars WASHINGTON (July 21,
Legislation codifies FDA’s science-based approach to biosimilar review by limiting comparative efficacy studies WASHINGTON (July 15, 2026) — The Biosimilars Council and the Association for
Biosimilar Red Tape Elimination Act and Medication Affordability and Patent Integrity Act address longstanding barriers inhibiting patient access to lower-cost prescription options WASHINGTON (June 17,
Skinny Labels are vital for U.S. patient affordability; Calls on Congress to act WASHINGTON (June 3, 2026) — The Association for Accessible Medicines commented on
Highlights commitment and rigorous holistic approach to quality medicines WASHINGTON (June 3, 2026) — The Association for Accessible Medicines today commented on a hearing held
Improving patient access to affordable high-quality medicines is a core value of companies that develop and manufacture generic and biosimilar medicines. Our companies produce and distribute
Thanks President and Administration for recognizing importance of generics WASHINGTON (May 18, 2026) — The Association for Accessible Medicines commented on the announcement today that
